Kiniksa Q4 rev. down 40% YoY, FY22 rev. down 49% YoY.

• Kiniksa Pharmaceuticals reports Q2 2023 revenue of $2.3mln, up 18.5% YoY • Kiniksa reports net loss of $33.3mln, compared to $28.6mln in Q2 2022 • Kiniksa's net loss per share is $0.34, compared to $0.31 in Q2 2022 • Kiniksa's R&D expenses increased to $26.6mln, compared to $19.9mln in Q2 2022 • Kiniksa's SG&A expenses increased to $30.5mln, compared to $22.1mln in Q2 2022

Kiniksa Pharmaceuticals International, plc (KNSA) has released its second-quarter 2023 financial results, indicating a significant increase in revenue but a substantial net loss. The company reported a revenue of $2.3 million, up by 18.5% year-over-year (YoY) compared to $1.94 million in Q2 2022 [1]. Despite the revenue growth, Kiniksa reported a net loss of $33.3 million, compared to a net loss of $28.6 million in the same period last year. The net loss per share increased to $0.34, from $0.31 in Q2 2022.

Research and Development (R&D) expenses for Kiniksa rose to $26.6 million in Q2 2023, a significant increase from $19.9 million in Q2 2022. Similarly, Sales, General, and Administrative (SG&A) expenses increased to $30.5 million, up from $22.1 million in the previous year. These increases reflect the company's continued investment in its pipeline and operational infrastructure.

Kiniksa's financial performance highlights the company's ongoing commitment to innovation in the biopharmaceutical sector. The reported figures underscore the challenges faced by clinical and commercial-stage biopharmaceutical companies in balancing growth and profitability. Investors should closely monitor Kiniksa's progress and future financial reports for insights into its long-term strategy and potential for success.

References:
[1] https://www.stocktitan.net/news/KNSA/